天津中医药2023，Vol.40Issue(12)：1575-1580,6.DOI:10.11656/j.issn.1672-1519.2023.12.13
基于《医疗机构中成药遴选专家共识》的血必净注射液遴选评价
Selection evaluation of Xuebijing Injection by the Experts Consensus on the Selection of Chinese Patent Medicine in Medical Institutions
摘要
Abstract
[Objective]To provide objective and accurate suggestions for the selection and rational use of Chinese patent medicines in medical institutions by carrying out the multi-dimensional evaluation of Xuebijing Injection.[Methods]According to the Expert Consensus on the Selection of Chinese Patent Drugs in Medical Institutions,Xuebijing Injection was comprehensively and systematically evaluated.[Results]The total score of Xuebijing injection is 71.0 points,including 19.0 points for safety,17.5 points for effectiveness,7.0 points for economy,8.0 points for innovation,4.5 points for suitability,7.0 points for accessibility and 8.0 points for inheritance.In terms of effectiveness,Xuebijing's clinical indications are irreplaceable,filling the gap in the treatment of sepsis and serving as the only injection among the"three drugs and three formulas",with definite therapeutic effects;in terms of safety,real-world data shows that Xuebijing has relatively high safety;In terms of innovation,Xuebijing has clear pharmacological effects and clear pharmacokinetics;in terms of suitability,Xuebijing has clear clinical positioning and storage,but poor compliance;in terms of accessibility,Xuebijing ensures supply,has strong affordability for patients,and has strong production enterprise strength;in terms of inheritance,Xuebijing originates from classic and famous formulas,with prominent characteristics of traditional Chinese medicine;in terms of economy,although the daily average cost is relatively high,it brings pharmacoeconomic advantages by reducing patient mortality.[Conclusion]Xuebijing has good clinical value and the recommended level of Xuebijing Injection is"recommended".关键词
血必净注射液/《医疗机构中成药遴选专家共识》/药品遴选/中成药/遴选评价Key words
Xuebijing Injection/Experts Consensus on the Selection of Chinese Patent Medicine in Medical Institutions/drug selection/Chinese patent medicine/selection evaluation分类
医药卫生引用本文复制引用
鞠晓宇,赵越,程杰..基于《医疗机构中成药遴选专家共识》的血必净注射液遴选评价[J].天津中医药,2023,40(12):1575-1580,6.基金项目
河北省中医药管理局指令性科研计划项目(2022027). （2022027）
